^
    21h
    A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy (clinicaltrials.gov)
    P2, N=20, Recruiting, M.D. Anderson Cancer Center | Trial primary completion date: Apr 2026 --> Dec 2027
    Trial primary completion date • Minimal residual disease • Circulating tumor DNA
    |
    Signatera™
    |
    Tevimbra (tislelizumab-jsgr) • Fruzaqla (fruquintinib)
    1d
    Fruquintinib In Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies in South Korea Patients (FIRST-K) (clinicaltrials.gov)
    P2, N=88, Not yet recruiting, Korea University Anam Hospital
    New P2 trial
    |
    Vectibix (panitumumab) • Fruzaqla (fruquintinib)
    5d
    Dual-targeted approaches in cancer therapy: integrating siRNA and chemotherapy for improved outcomes. (PubMed, 3 Biotech)
    Early clinical candidates, such as EZN-3042 and ALN-VSP, achieved target engagement and biological activity, while limitations included variable tumour uptake, dose-limiting toxicities, and complex pharmacokinetic behaviour. Translation to clinical practice will depend on optimised delivery platforms, reproducible pharmacokinetic/pharmacodynamic synchronisation, and rigorous evaluation of safety and off-target effects. Overall, current evidence highlights substantial potential for siRNA-drug co-delivery while emphasizing key challenges to overcome in achieving durable clinically meaningful outcomes.
    Review • Journal
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • MET (MET proto-oncogene, receptor tyrosine kinase) • BCL2 (B-cell CLL/lymphoma 2) • MUC1 (Mucin 1) • BIRC5 (Baculoviral IAP repeat containing 5)
    5d
    Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies (clinicaltrials.gov)
    P1, N=19, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Mar 2027
    Trial completion date
    |
    Koselugo (selumetinib) • Recentin (cediranib)
    6d
    STARS-RC10: Efficacy and Safety Comparison of Short-course Radiotherapy Followed by CapeOX Chemotherapy Plus Toripalimab With or Without Concurrent Surufatinib in Neoadjuvant Therapy for Mid-to-low Localized Rectal Cancer of High-risk Criteria (clinicaltrials.gov)
    P2/3, N=212, Recruiting, The First Hospital of Jilin University
    New P2/3 trial
    |
    Loqtorzi (toripalimab-tpzi) • capecitabine • oxaliplatin • Sulanda (surufatinib)
    6d
    Computational validation of inhibitors for human phosphatidylinositol 4-phosphate 5-kinase-type 1 α protein implicated in cancer. (PubMed, J Biomol Struct Dyn)
    Four protein kinase inhibitors, R547, GDC-0879, JNJ-7706621 and ABT-869 were found to bind hPIP5K1α via a stable complex formation. The hit molecules display favorable ADME properties and are predicted to be non-carcinogenic. The hit molecules in particular R547, have better binding free energies compared to reference molecule, ISA-2011B.
    Journal
    |
    PIP5K1A (Phosphatidylinositol-4-Phosphate 5-Kinase Type 1 Alpha)
    |
    GDC 0879 • linifanib (ABT-869) • R-547
    7d
    Real-world pharmacovigilance and molecular mechanisms of fruquintinib: SRC and STAT3 as potential off-target mediators of proteinuria. (PubMed, Front Pharmacol)
    This clinical association might involve both classical vascular endothelial growth factor receptor blockade and the potential off target structural interactions of SRC and STAT3. These insights underscore the importance of early renal monitoring and offer structural insights into the drug's safety profile.
    Journal • Adverse events • Real-world evidence
    |
    STAT3 (Signal Transducer And Activator Of Transcription 3)
    |
    Fruzaqla (fruquintinib)
    8d
    A Clinical Study of Iparomlimab and Tuvonralimab Combined With Fruquintinib and Heterogeneous Radiotherapy Versus Fruquintinib as Third-Line and Subsequent-Line Treatment for Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Huazhong University of Science and Technology
    New P2 trial
    |
    Fruzaqla (fruquintinib) • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    8d
    Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers (clinicaltrials.gov)
    P1/2, N=31, Recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2027 --> Dec 2029 | Trial primary completion date: Dec 2026 --> Dec 2028
    Trial completion date • Trial primary completion date
    |
    Fotivda (tivozanib)
    10d
    A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML) (clinicaltrials.gov)
    P1, N=18, Recruiting, Memorial Sloan Kettering Cancer Center | N=36 --> 18
    Enrollment change
    |
    FLT3 (Fms-related tyrosine kinase 3) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
    |
    IDH1 mutation • IDH2 mutation • FLT3 mutation
    |
    Xospata (gilteritinib) • Tibsovo (ivosidenib) • Idhifa (enasidenib)
    12d
    Pre-Clinical Combination Targeting VEGF and PI3K in a Rare, Aggressive Mixed Endometrial Carcinoma: An Applied Case Report. (PubMed, Cancer Res Commun)
    Cediranib demonstrated synergy with BKM120, significantly reducing organoid growth. It highlights that high-throughput sequencing for individual patient tumors and generation of patient-derived models are feasible in endometrial cancer. This preclinical model may assist clinical decision and personalized therapy requiring validation in prospective studies.
    Preclinical • Journal
    |
    PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • ARID1A (AT-rich interaction domain 1A) • VEGFA (Vascular endothelial growth factor A) • CTNNB1 (Catenin (cadherin-associated protein), beta 1)
    |
    buparlisib (AN2025) • Recentin (cediranib)
    13d
    VAG-3+7-G: VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML (clinicaltrials.gov)
    P3, N=300, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China | Initiation date: Jan 2026 --> Apr 2026
    Trial initiation date
    |
    FLT3 (Fms-related tyrosine kinase 3) • BCL2 (B-cell CLL/lymphoma 2)
    |
    FLT3-ITD mutation • FLT3-TKD mutation
    |
    Venclexta (venetoclax) • cytarabine • Xospata (gilteritinib) • azacitidine • daunorubicin • idarubicin hydrochloride